SEARCH:   Advanced

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Fujii, S.-i. Articles by Lotze, M. T. Search for Related Content PubMed PubMed Citation Articles by Fujii, S.-i. Articles by Lotze, M. T. Related Collections Immunobiology Immunotherapy Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 1 October 2001, Vol. 98, No. 7, pp. 2143-2151 IMMUNOBIOLOGY Interleukin-10 promotes the maintenance of antitumor CD8+ T-cell effector function in situ Shin-ichiro Fujii, Kanako Shimizu, Takashi Shimizu, and Michael T. Lotze From the Department of Surgery, University of Pittsburgh School of Medicine, and the Division of Biological Therapeutics, University of Pittsburgh Cancer Institute, PA. Interleukin-10 (IL-10) is a multifunctional cytokine that can exert suppressive and stimulatory effects on T cells. It was investigated whether IL-10 could serve as an immunostimulant for specific CD8+ cytotoxic T cell (CTL) in vivo after vaccination and, if so, under what conditions. In tumor prevention models, administration of IL-10 before, or soon after, peptide-pulsed primary dendritic cell immunization resulted in immune suppression and enhanced tumor progression. Injection of IL-10, however, just after a booster vaccine significantly enhanced antitumor immunity and vaccine efficacy. Analysis of spleen cells derived from these latter animals 3 weeks after IL-10 treatment revealed that the number of CD8+ CD44hi CD122+ T cells had increased and that antigen-specific proliferation in vitro was enhanced. Although cytotoxicity assays did not support differences between the various treatment groups, 2 more sensitive assays measuring antigen-specific interferon- production at the single-cell level demonstrated increases in the number of antigen-specific responder T cells in animals in the vaccine/IL-10 treatment group. Thus, IL-10 may maintain the number of antitumor CD8+ T cells. In adoptive transfer studies, the ability of IL-10 to maintain CTL function could be enhanced by the depletion of CD4+ T cells. This suggests that IL-10 mediates contrasting effects on both CD4+ and CD8+ T cells that result in either immune dampening or immune potentiation in situ, respectively. Appreciation of this dichotomy in IL-10 immunobiology may allow for the design of more effective cancer vaccines designed to activate and maintain specific CD8+ T-cell effector function in situ. © 2001 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: X. Zhang, E. Deriaud, X. Jiao, D. Braun, C. Leclerc, and R. Lo-Man Type I interferons protect neonates from acute inflammation through interleukin 10-producing B cells J. Exp. Med., May 14, 2007; 204(5): 1107 - 1118. [Abstract] [Full Text] [PDF] S. Koido, E. Hara, S. Homma, A. Torii, M. Mitsunaga, S. Yanagisawa, Y. Toyama, H. Kawahara, M. Watanabe, S. Yoshida, et al. Streptococcal Preparation OK-432 Promotes Fusion Efficiency and Enhances Induction of Antigen-Specific CTL by Fusions of Dendritic Cells and Colorectal Cancer Cells J. Immunol., January 1, 2007; 178(1): 613 - 622. [Abstract] [Full Text] [PDF] S. Inoue, W. W. Leitner, B. Golding, and D. Scott Inhibitory effects of B cells on antitumor immunity. Cancer Res., August 1, 2006; 66(15): 7741 - 7747. [Abstract] [Full Text] [PDF] S. Mocellin, F. M. Marincola, and H. A. Young Interleukin-10 and the immune response against cancer: a counterpoint J. Leukoc. Biol., November 1, 2005; 78(5): 1043 - 1051. [Abstract] [Full Text] [PDF] S. Koido, E. Hara, S. Homma, A. Torii, Y. Toyama, H. Kawahara, M. Watanabe, K. Yanaga, K. Fujise, H. Tajiri, et al. Dendritic Cells Fused with Allogeneic Colorectal Cancer Cell Line Present Multiple Colorectal Cancer-Specific Antigens and Induce Antitumor Immunity against Autologous Tumor Cells Clin. Cancer Res., November 1, 2005; 11(21): 7891 - 7900. [Abstract] [Full Text] [PDF] J. Huang, T. Tatsumi, E. Pizzoferrato, N. Vujanovic, and W. J. Storkus Nitric Oxide Sensitizes Tumor Cells to Dendritic Cell-Mediated Apoptosis, Uptake, and Cross-Presentation Cancer Res., September 15, 2005; 65(18): 8461 - 8470. [Abstract] [Full Text] [PDF] C. Dercamp, K. Chemin, C. Caux, G. Trinchieri, and A. P. Vicari Distinct and Overlapping Roles of Interleukin-10 and CD25+ Regulatory T Cells in the Inhibition of Antitumor CD8 T-Cell Responses Cancer Res., September 15, 2005; 65(18): 8479 - 8486. [Abstract] [Full Text] [PDF] M. Scheckelhoff and G. S. Deepe Jr. A Deficiency in Gamma Interferon or Interleukin-10 Modulates T-Cell-Dependent Responses to Heat Shock Protein 60 from Histoplasma capsulatum Infect. Immun., April 1, 2005; 73(4): 2129 - 2134. [Abstract] [Full Text] [PDF] S. Beckebaum, X. Zhang, X. Chen, Z. Yu, A. Frilling, G. Dworacki, H. Grosse-Wilde, C. E. Broelsch, G. Gerken, and V. R. Cicinnati Increased Levels of Interleukin-10 in Serum from Patients with Hepatocellular Carcinoma Correlate with Profound Numerical Deficiencies and Immature Phenotype of Circulating Dendritic Cell Subsets Clin. Cancer Res., November 1, 2004; 10(21): 7260 - 7269. [Abstract] [Full Text] [PDF] M. Urosevic, T. Maier, B. Benninghoff, H. Slade, G. Burg, and R. Dummer Mechanisms Underlying Imiquimod-Induced Regression of Basal Cell Carcinoma In Vivo Arch Dermatol, October 1, 2003; 139(10): 1325 - 1332. [Abstract] [Full Text] [PDF] H. J. J. van der Vliet, J. W. Molling, N. Nishi, A. J. Masterson, W. Kolgen, S. A. Porcelli, A. J. M. van den Eertwegh, B. M. E. von Blomberg, H. M. Pinedo, G. Giaccone, et al. Polarization of V{alpha}24+ V{beta}11+ Natural Killer T Cells of Healthy Volunteers and Cancer Patients Using {alpha}-Galactosylceramide-loaded and Environmentally Instructed Dendritic Cells Cancer Res., July 15, 2003; 63(14): 4101 - 4106. [Abstract] [Full Text] [PDF] S.-i. Fujii, K. Shimizu, F. Koji, and F. Kawano Malignant counterpart of myeloid dendritic cell (DC) belonging to acute myelogenous leukemia (AML) exhibits a dichotomous immunoregulatory potential J. Leukoc. Biol., January 1, 2003; 73(1): 82 - 90. [Abstract] [Full Text] [PDF] Y. Miura, C. J. Thoburn, E. C. Bright, W. Chen, S. Nakao, and A. D. Hess Cytokine and chemokine profiles in autologous graft-versus-host disease (GVHD): interleukin 10 and interferon gamma may be critical mediators for the development of autologous GVHD Blood, September 18, 2002; 100(7): 2650 - 2658. [Abstract] [Full Text] [PDF] C.-Q. Xia and K.-J. Kao Heparin Induces Differentiation of CD1a+ Dendritic Cells from Monocytes: Phenotypic and Functional Characterization J. Immunol., February 1, 2002; 168(3): 1131 - 1138. [Abstract] [Full Text] [PDF]

	Copyright © 2001 by American Society of Hematology         Online ISSN: 1528-0020